130 related articles for article (PubMed ID: 18606527)
21. Animal-free production of ccc-supercoiled plasmids for research and clinical applications.
Schleef M; Schmidt T
J Gene Med; 2004 Feb; 6 Suppl 1():S45-53. PubMed ID: 14978750
[TBL] [Abstract][Full Text] [Related]
22. Tumor antigen-specific FOXP3+ CD4 T cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts.
Jandus C; Bioley G; Dojcinovic D; Derré L; Baitsch L; Wieckowski S; Rufer N; Kwok WW; Tiercy JM; Luescher IF; Speiser DE; Romero P
Cancer Res; 2009 Oct; 69(20):8085-93. PubMed ID: 19808957
[TBL] [Abstract][Full Text] [Related]
23. Differential capacity of chaperone-rich lysates in cross-presenting human endogenous and exogenous melanoma differentiation antigens.
Bleifuss E; Bendz H; Sirch B; Thompson S; Brandl A; Milani V; Graner MW; Drexler I; Kuppner M; Katsanis E; Noessner E; Issels RD
Int J Hyperthermia; 2008 Dec; 24(8):623-37. PubMed ID: 18608582
[TBL] [Abstract][Full Text] [Related]
24. Fine structural variations of alphabetaTCRs selected by vaccination with natural versus altered self-antigen in melanoma patients.
Wieckowski S; Baumgaertner P; Corthesy P; Voelter V; Romero P; Speiser DE; Rufer N
J Immunol; 2009 Oct; 183(8):5397-406. PubMed ID: 19786555
[TBL] [Abstract][Full Text] [Related]
25. Vaccination with combination of Fit3L and RANTES in a DNA prime-protein boost regimen elicits strong cell-mediated immunity and antitumor effect.
Song S; Liu C; Wang J; Zhang Y; You H; Wang Y; Liu F; Sun S
Vaccine; 2009 Feb; 27(7):1111-8. PubMed ID: 19100302
[TBL] [Abstract][Full Text] [Related]
26. Induction of specific human primary immune responses to a Semliki Forest virus-based tumor vaccine in a Trimera mouse model.
Ni B; Gao W; Zhu B; Lin Z; Jia Z; Zhou W; Zhao J; Wang L; Wu Y
Cancer Immunol Immunother; 2005 May; 54(5):489-98. PubMed ID: 15750833
[TBL] [Abstract][Full Text] [Related]
27. Magnetic separation of melanoma-specific cytotoxic T lymphocytes from a vaccinated melanoma patient's blood using MHC/peptide complex-conjugated bacterial magnetic particles.
Takahashi M; Akiyama Y; Ikezumi J; Nagata T; Yoshino T; Iizuka A; Yamaguchi K; Matsunaga T
Bioconjug Chem; 2009 Feb; 20(2):304-9. PubMed ID: 19143499
[TBL] [Abstract][Full Text] [Related]
28. Characterization of a MAGE-1-derived HLA-A24 epitope-specific CTL line from a Japanese metastatic melanoma patient.
Akiyama Y; Maruyama K; Tai S; Komiyama M; Iizuka A; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
Anticancer Res; 2009 Feb; 29(2):647-55. PubMed ID: 19331215
[TBL] [Abstract][Full Text] [Related]
29. Naked plasmid DNA formulation: effect of different disaccharides on stability after lyophilisation.
Quaak SG; Haanen JB; Beijnen JH; Nuijen B
AAPS PharmSciTech; 2010 Mar; 11(1):344-50. PubMed ID: 20204715
[TBL] [Abstract][Full Text] [Related]
30. The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells.
François V; Ottaviani S; Renkvist N; Stockis J; Schuler G; Thielemans K; Colau D; Marchand M; Boon T; Lucas S; van der Bruggen P
Cancer Res; 2009 May; 69(10):4335-45. PubMed ID: 19435913
[TBL] [Abstract][Full Text] [Related]
31. Strategies to enhance the therapeutic activity of cancer vaccines: using melanoma as a model.
Berinstein NL
Ann N Y Acad Sci; 2009 Sep; 1174():107-17. PubMed ID: 19769743
[TBL] [Abstract][Full Text] [Related]
32. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma.
Nicholaou T; Ebert LM; Davis ID; McArthur GA; Jackson H; Dimopoulos N; Tan B; Maraskovsky E; Miloradovic L; Hopkins W; Pan L; Venhaus R; Hoffman EW; Chen W; Cebon J
Clin Cancer Res; 2009 Mar; 15(6):2166-73. PubMed ID: 19276262
[TBL] [Abstract][Full Text] [Related]
33. Immunoregulatory T cells in the peripheral blood of melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination.
Nakai N; Katoh N; Kitagawa T; Ueda E; Takenaka H; Kishimoto S
J Dermatol Sci; 2009 Apr; 54(1):31-7. PubMed ID: 19157789
[TBL] [Abstract][Full Text] [Related]
34. Development of a highly productive and scalable plasmid DNA production platform.
Listner K; Bentley L; Okonkowski J; Kistler C; Wnek R; Caparoni A; Junker B; Robinson D; Salmon P; Chartrain M
Biotechnol Prog; 2006; 22(5):1335-45. PubMed ID: 17022672
[TBL] [Abstract][Full Text] [Related]
35. mRNA-based cancer vaccine: prevention of B16 melanoma progression and metastasis by systemic injection of MART1 mRNA histidylated lipopolyplexes.
Mockey M; Bourseau E; Chandrashekhar V; Chaudhuri A; Lafosse S; Le Cam E; Quesniaux VF; Ryffel B; Pichon C; Midoux P
Cancer Gene Ther; 2007 Sep; 14(9):802-14. PubMed ID: 17589432
[TBL] [Abstract][Full Text] [Related]
36. MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency.
Godet Y; Moreau-Aubry A; Guilloux Y; Vignard V; Khammari A; Dreno B; Jotereau F; Labarriere N
J Exp Med; 2008 Oct; 205(11):2673-82. PubMed ID: 18936238
[TBL] [Abstract][Full Text] [Related]
37. DNA vaccines: successes and limitations in cancer and infectious disease.
Lowe DB; Shearer MH; Kennedy RC
J Cell Biochem; 2006 May; 98(2):235-42. PubMed ID: 16440328
[TBL] [Abstract][Full Text] [Related]
38. [Present status of basic studies and development of DNA vaccines].
Kurane I
Nihon Rinsho; 1999 Apr; 57(4):975-81. PubMed ID: 10222799
[TBL] [Abstract][Full Text] [Related]
39. Plasmid DNA for pharmaceutical applications.
Schleef M; Schmidt T; Flaschel E
Dev Biol (Basel); 2000; 104():25-31. PubMed ID: 11713820
[TBL] [Abstract][Full Text] [Related]
40. Characterization of preexisting MAGE-A3-specific CD4+ T cells in cancer patients and healthy individuals and their activation by protein vaccination.
Tsuji T; Altorki NK; Ritter G; Old LJ; Gnjatic S
J Immunol; 2009 Oct; 183(7):4800-8. PubMed ID: 19734225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
